Demonstrate the safety of anticoagulant DOACs in the treatment of venous thromboembolism in patients with chronic renal failure
Feb 14, 2025
Professor Mo Hye-jin of Surgery at Boramae Hospital in Seoul Metropolitan City, operated by Seoul National University Hospital, presented the results of a study on the stability of direct oral anticoagulants (DOACs) for the treatment of venous thromboembolism in hemodialysis patients with Professor Kim Hyang-kyung of surgery at Ewha Womans University Mokdong Hospital, Professor Yang Seung-bu of radiology at Nowon Eulji Hospital, and Professor Kwon Young-joo of kidney medicine at Korea University Guro Hospital.
Venous thromboembolism is a common vascular disease, including pulmonary embolism and deep vein thrombosis, with a lifetime risk of developing in adults of approximately 8%. In addition, patients with chronic renal failure, who are on the rise every year, have a much higher risk of venous thromboembolism than the general population, so the treatment of venous thromboembolism in patients with chronic renal failure is an important issue.
For venous thromboembolism, anticoagulant therapy is used as the main treatment, and direct oral anticoagulants (DOACs) are less at risk of complications such as bleeding and easier to take and manage than existing anticoagulants, so their use is gradually increasing.
However, studies evaluating the safety of DOACs in the treatment of venous thromboembolism in patients with chronic renal failure undergoing dialysis have been insufficient.
In response, Professor Mo Hye-jin's research team conducted a retrospective analysis of chronic renal failure patients who took DOACs to treat thromboembolism from the National Health Insurance Corporation database from 2008 to 2019, and as a result, the use of DOACs to treat venous thromboembolism in dialysis patients showed no significant difference in terms of major complications.
The research team analyzed gastrointestinal bleeding, intracranial bleeding complications, and overall mortality in patients receiving hemodialysis (Group A, 118) and those not receiving dialysis (Group B, 227) who took DOACs to treat thromboembolism, matched factors such as age, gender, and underlying disease.
From 2008 to 2019, the use of DOACs gradually increased in patients with chronic renal failure regardless of dialysis status. The overall mortality rate per 100 years (person-years) was 38.1 in group A undergoing hemodialysis and 10.5 in group B without hemodialysis, significantly higher risk of death in group A.
On the other hand, considering death as a competing risk, there was no significant difference between groups A and B in the incidence of gastrointestinal bleeding and intracranial bleeding.
Professor Mo Hye-jin said, "Through this study, we wanted to provide information on the treatment of venous thromboembolism, which is common in patients with end-stage renal failure, especially the use of DOACs that are easy to take and manage, to help patients with chronic renal failure to provide the best treatment for venous thromboembolism and reduce complications."
The study was published in the January 2025 issue of Kidney Research and Clinical Practice, an SCI-level international academic journal.
Venous thromboembolism is a common vascular disease, including pulmonary embolism and deep vein thrombosis, with a lifetime risk of developing in adults of approximately 8%. In addition, patients with chronic renal failure, who are on the rise every year, have a much higher risk of venous thromboembolism than the general population, so the treatment of venous thromboembolism in patients with chronic renal failure is an important issue.
For venous thromboembolism, anticoagulant therapy is used as the main treatment, and direct oral anticoagulants (DOACs) are less at risk of complications such as bleeding and easier to take and manage than existing anticoagulants, so their use is gradually increasing.
However, studies evaluating the safety of DOACs in the treatment of venous thromboembolism in patients with chronic renal failure undergoing dialysis have been insufficient.
In response, Professor Mo Hye-jin's research team conducted a retrospective analysis of chronic renal failure patients who took DOACs to treat thromboembolism from the National Health Insurance Corporation database from 2008 to 2019, and as a result, the use of DOACs to treat venous thromboembolism in dialysis patients showed no significant difference in terms of major complications.
The research team analyzed gastrointestinal bleeding, intracranial bleeding complications, and overall mortality in patients receiving hemodialysis (Group A, 118) and those not receiving dialysis (Group B, 227) who took DOACs to treat thromboembolism, matched factors such as age, gender, and underlying disease.
From 2008 to 2019, the use of DOACs gradually increased in patients with chronic renal failure regardless of dialysis status. The overall mortality rate per 100 years (person-years) was 38.1 in group A undergoing hemodialysis and 10.5 in group B without hemodialysis, significantly higher risk of death in group A.
On the other hand, considering death as a competing risk, there was no significant difference between groups A and B in the incidence of gastrointestinal bleeding and intracranial bleeding.
Professor Mo Hye-jin said, "Through this study, we wanted to provide information on the treatment of venous thromboembolism, which is common in patients with end-stage renal failure, especially the use of DOACs that are easy to take and manage, to help patients with chronic renal failure to provide the best treatment for venous thromboembolism and reduce complications."
The study was published in the January 2025 issue of Kidney Research and Clinical Practice, an SCI-level international academic journal.
|
This article was translated by Naver AI translator.
